Anti-atherogenic activity of the calcium channel blocker isradipine (PN-200-110): a novel effect on matrix synthesis independent of calcium channel blockade.
D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D001161:Arteriosclerosis / Q000473:pathology / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002478:Cells, Cultured; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D004036:Diet, Atherogenic; D006801:Humans; D006965:Hyperplasia; D017275:Isradipine; D014176:Protein Biosynthesis; D011725:Pyridines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats
D002121:Calcium Channel Blockers; D002791:Cholesterol, Dietary; D011725:Pyridines; D017275:Isradipine